Marex Group plc (‘Marex’ or the ‘Group’; NASDAQ: MRX), the diversified global financial services platform, today announces that it will take a minority stake in Ruminant Biotech (“RBT”), a New Zealand-based business that has developed technology to reduce methane emissions from pasture-based livestock.
RBT will use the funds to advance its development of the technology, which trials have indicated can reduce methane production in animals treated with a single dose of the product for a period of 100 days. These funds will also help progress regulatory approvals in priority markets globally. The reduction in methane as a result of the use of this technology can be quantified and converted into carbon credits, creating a pathway into the growing carbon market.
Marex’s investment in RBT aligns with its strategy to grow its environmental business and allows it to access to a new stream of carbon credits and potentially tap into a wider carbon client base. It also creates an opportunity for Marex to further diversify its emissions reduction offering, leaving it well placed to support its clients as they transition to a low carbon economy.
As part of its investment, it has also been agreed that Marex will act as exclusive broker and market maker in respect of a number of RBT’s own carbon credits generated by the project.
“This investment is an exciting opportunity for Marex to gain further access to high-quality carbon credits which expand our range of products available to clients. We see significant potential in this investment for the future, and it strengthens our growing position as a provider for carbon credits for the region and globally.”Nigel Brunel Managing Director New Zealand, Marex
“This investment positions us to commercialize our technology with a scalable business model that rewards on-farm emissions reductions through carbon markets. We’re excited to unlock new ways to reward farmers for reducing emissions, while helping industry and governments meet their climate goals. We’re confident that if we can get this right, adoption will follow.”Tom Breen CEO of Ruminant Biotech
